BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 29, 2023
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

Vascular system
Cardiovascular

Eli Lilly presents the preclinical profile of LY-3473329

Aug. 30, 2023
No Comments
Human lipoprotein(a) (Lp(a)) is a lipoprotein complex composed of a low-density lipoprotein (LDL) particle and a large highly polymorphic glycoprotein named apolipoprotein (a) (apo(a)). There is evidence that Lp(a) is linked to cardiovascular disorder risk.
Read More
Colorful illustration of the heart
Endocrine/Metabolic

AT-02, a humanized IgG1-peptide fusion reagent that potently binds cardiac amyloid

Aug. 30, 2023
No Comments
At the recent ESC Congress, researchers from University of Tennessee and Attralus Inc. presented preclinical data on the novel pan-amyloid-binding peptide fusion immunoglobulin AT-02, which is being developed for the treatment of amyloidosis.
Read More
Hematologic

Epigenetic modifier modulator CS-014 shows good clot prevention profile in vivo

Aug. 30, 2023
No Comments
Under pathologic conditions such as vascular injury or atherosclerosis, the hyperactivation of platelets may lead to occlusive thrombus formation, myocardial infarction or stroke. Although there are several targets for clot prevention validated clinically, these strategies may present bleeding risk as a limitation. Researchers from the University of Michigan have reported on CS-014, a histone deacetylase (HDAC) inhibitor aimed to reduce clot formation without risk of bleeding.
Read More
DNA double helix with sand hour glass
Biomarkers

Biomarker brainteaser: Aging? Or just changing?

Aug. 30, 2023
By Anette Breindl
No Comments
“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor. Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.” And “we are not there … we are actually quite far from there.”
Read More
3D illustration of Cryptosporidium oocysts releasing sporozoites
Infection

Novartis discloses a novel soft-drug strategy for cryptosporidiosis

Aug. 29, 2023
No Comments
Cryptosporidiosis is a parasitic infection caused by Cryptosporidium where infected individuals develop profuse watery diarrhea and enteric symptoms such as abdominal pain. In immunocompromised or malnourished children, the infection may become chronic and lead to significant morbidity and mortality rates.
Read More
Colorized transmission electron micrograph of SARS-CoV-2.
Infection

Next-generation oral SARS-CoV-2 Mpro inhibitor disclosed

Aug. 29, 2023
No Comments
Viral proteases are well-established therapeutic targets in HIV and hepatitis C virus infections. Following the recent COVID-19 pandemic, one of the strategies in place is SARS-CoV-2 main protease (Mpro) inhibition, given the crucial role of SARS-CoV-2 Mpro in the replication of the virus.
Read More
Central nervous system
Neurology/Psychiatric

Methodological, target breadth begets optimism for movement disorder progress

Aug. 29, 2023
By Anette Breindl
No Comments
“I am not a fortune teller, nor am I a gambler. I will make no bets,” Lorraine Kalia told the audience at the 2023 International Congress of Parkinson’s Disease and Movement Disorders. “But I am optimistic.” At the meeting, which is being held in Copenhagen this week, Kalia, who is a scientist at Toronto Western Hospital’s Krembil Brain Institute and at the University of Toronto’s Tanz Centre for Research in Neurodegenerative Diseases, was giving an overview of “Emerging targets in the clinic” in a plenary session on “Therapeutic strategies for the future.”
Read More
Cancer cell targeted in crosshairs
Cancer

Highly potent and selective MASTL inhibitors disclosed

Aug. 25, 2023
No Comments
Microtubule-associated serine/threonine kinase-like (MASTL) is involved in cell proliferation, migration, and invasion and for that reason is considered a relevant therapeutic target for cancer treatment. At the recent ACS Fall meeting, researchers from Pfizer Inc. presented the discovery and characterization of a series of potent and selective MASTL inhibitors for the treatment of cancer.
Read More
Illustration highlighting the brain's reward circuit.
Substance Use & Poisoning

First-in-class RXFP3 negative allosteric modulator RLX-33 prevents alcohol relapse in rats

Aug. 24, 2023
No Comments
New treatment options are needed for the prevention of relapse to alcohol use, the major problem in the treatment of alcohol dependence in humans. The neuropeptide relaxin-3/RXFP3 plays a relevant role in the motivation for the reward process and is considered a possible therapeutic target in addictive behaviors.
Read More
Brain and encephalography
Neurology/Psychiatric

NS-041, a novel KCNQ2/3 activator for the treatment of epilepsy, presented at ACS meeting

Aug. 23, 2023
No Comments
Voltage-gated potassium channels (KCNQ) control neural excitability and their dysfunction leads to neuronal channelopathies frequently related to...
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 2997 2998 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 28, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 28, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing